{"id":31100,"date":"2025-05-21T08:34:40","date_gmt":"2025-05-21T12:34:40","guid":{"rendered":"https:\/\/www.cosprc.ca\/?p=31100"},"modified":"2025-05-21T08:40:04","modified_gmt":"2025-05-21T12:40:04","slug":"enonce-de-position-conjoint-sur-la-fin-a-la-commercialisation-du-betoptic-s","status":"publish","type":"post","link":"https:\/\/www.cosprc.ca\/fr\/enonce-de-position-conjoint-sur-la-fin-a-la-commercialisation-du-betoptic-s\/","title":{"rendered":"\u00c9nonc\u00e9 de position conjoint sur la fin \u00e0 la commercialisation du Betoptic S"},"content":{"rendered":"
\n
\"\"<\/figure><\/div>\n\n\n

Novartis met fin \u00e0 la commercialisation du Betoptic S (b\u00e9taxolol 0,25\u00a0%) \u00e0 l\u2019\u00e9chelle mondiale. Les stocks existants au Canada devraient \u00eatre \u00e9puis\u00e9s d\u2019ici la fin de l\u2019ann\u00e9e. Il n\u2019existe aucune autre solution ophtalmique de b\u00e9taxolol commercialis\u00e9e au Canada.\u00a0 Novartis a indiqu\u00e9 qu\u2019il s\u2019agit d\u2019une d\u00e9cision mondiale irr\u00e9versible. L\u2019arr\u00eat de commercialisation a d\u00e9j\u00e0 eu lieu dans d\u2019autres r\u00e9gions du monde. Nous avons cr\u00e9\u00e9 un petit document \u00e0 l\u2019intention de nos coll\u00e8gues en pr\u00e9vision de ce changement.

Novartis met fin \u00e0 la commercialisation du Betoptic S (b\u00e9taxolol 0,25\u00a0%) \u00e0 l\u2019\u00e9chelle mondiale. Les stocks existants au Canada devraient \u00eatre \u00e9puis\u00e9s d\u2019ici la fin de l\u2019ann\u00e9e. Il n\u2019existe aucune autre solution ophtalmique de b\u00e9taxolol commercialis\u00e9e au Canada.\u00a0 Novartis a indiqu\u00e9 qu\u2019il s\u2019agit d\u2019une d\u00e9cision mondiale irr\u00e9versible. L\u2019arr\u00eat de commercialisation a d\u00e9j\u00e0 eu lieu dans d\u2019autres r\u00e9gions du monde. Nous avons cr\u00e9\u00e9 un petit document \u00e0 l\u2019intention de nos coll\u00e8gues en pr\u00e9vision de ce changement.

Nous esp\u00e9rons que les professionnels de la sant\u00e9 accompagneront leurs patients durant l\u2019arr\u00eat du m\u00e9dicament. D\u2019autres strat\u00e9gies de prise en charge peuvent inclure le passage \u00e0 une autre classe de m\u00e9dicaments topiques pour le glaucome (p. ex. analogue de la prostaglandine, inhibiteur de l\u2019anhydrase carbonique, agoniste alpha) en l\u2019absence de contre-indication3<\/sup>, l\u2019augmentation de la disponibilit\u00e9 oculaire tout en diminuant l\u2019absorption syst\u00e9mique des autres traitements par la fermeture des paupi\u00e8res ou l\u2019occlusion\u00a0nasolacrymale4<\/sup>, la trab\u00e9culoplastie au laser5<\/sup>, la chirurgie du glaucome \u00e0 invasion minimale ou la chirurgie \u00e0 effraction minimale avec bulle de filtration6<\/sup>, ou encore la chirurgie du glaucome par incision7<\/sup>. Les besoins des patients et la disponibilit\u00e9 des traitements varieront selon les r\u00e9gions du pays. Nous vous remercions vous, professionnels de la sant\u00e9, de votre engagement continu \u00e0 offrir des soins d\u2019excellence \u00e0 l\u2019ensemble de la population canadienne.<\/p>\n\n\n\n

\n\n\n\n
    \n
  1. Stewart RH, Kimbrough RL, Ward RL.\u00a0Betaxolol\u00a0vs timolol. A six-month double-blind comparison. Arch Ophthalmol. Janv. 1986;104(1):46-8<\/li>\n\n\n\n
  2. Schoene RB, Abuan T, Ward RL, Beasley CH. Effects of topical\u00a0betaxolol, timolol, and placebo on pulmonary function in asthmatic bronchitis. Am J Ophthalmol. Janv. 1984;97(1):86-92<\/li>\n\n\n\n
  3. Li T, Lindsley K, Rouse B, Hong H, Shi Q, Friedman DS, Wormald R, Dickersin K. Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis. Ophthalmology. Janv. 2016;123(1):129-40<\/li>\n\n\n\n
  4. Flach AJ. The importance of eyelid closure and nasolacrimal occlusion following the ocular instillation of topical glaucoma medications, and the need for the universal inclusion of one of these techniques in all patient treatments and clinical studies. Trans Am Ophthalmol Soc. 2008;106:138-45<\/li>\n\n\n\n
  5. Li X, Wang W, Zhang X. Meta-analysis of selective laser trabeculoplasty versus topical medication in the treatment of open-angle glaucoma. BMC Ophthalmol. 19 ao\u00fbt 2015;15:107<\/li>\n\n\n\n
  6. Nichani P, Popovic MM, Schlenker MB, Park J, Ahmed IIK. Microinvasive glaucoma surgery: A review of 3476 eyes. Surv Ophthalmol. Sept-oct. 2021;66(5):714-742<\/li>\n\n\n\n
  7. Gedde SJ, Schiffman JC, Feuer WJ, Herndon LW, Brandt JD, Budenz DL; Tube versus Trabeculectomy Study Group. Treatment outcomes in the Tube Versus Trabeculectomy (TVT) study after five years of follow-up. Am J Ophthalmol. Mai 2012;153(5):789-803.e2<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Novartis met fin \u00e0 la commercialisation du Betoptic S (b\u00e9taxolol 0,25\u00a0%) \u00e0 l\u2019\u00e9chelle mondiale. Les stocks existants au Canada devraient \u00eatre \u00e9puis\u00e9s d\u2019ici la fin de l\u2019ann\u00e9e. Il n\u2019existe aucune autre solution ophtalmique de b\u00e9taxolol commercialis\u00e9e au Canada.\u00a0 Novartis a indiqu\u00e9 qu\u2019il s\u2019agit d\u2019une d\u00e9cision mondiale irr\u00e9versible. L\u2019arr\u00eat de commercialisation a d\u00e9j\u00e0 eu lieu dans […]<\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[305,306],"post_tag":[],"content_type":[326],"class_list":["post-31100","post","type-post","status-publish","format-standard","hentry","category-pour-les-ophtalmologistes","category-pour-les-residents-et-les-boursiers","content_type-enonce-de-principes-et-lignes-directrices"],"acf":[],"yoast_head":"\n\u00c9nonc\u00e9 de position conjoint sur la fin \u00e0 la commercialisation du Betoptic S - Practice Resource Centre<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cosprc.ca\/fr\/enonce-de-position-conjoint-sur-la-fin-a-la-commercialisation-du-betoptic-s\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u00c9nonc\u00e9 de position conjoint sur la fin \u00e0 la commercialisation du Betoptic S - Practice Resource Centre\" \/>\n<meta property=\"og:description\" content=\"Novartis met fin \u00e0 la commercialisation du Betoptic S (b\u00e9taxolol 0,25\u00a0%) \u00e0 l\u2019\u00e9chelle mondiale. Les stocks existants au Canada devraient \u00eatre \u00e9puis\u00e9s d\u2019ici la fin de l\u2019ann\u00e9e. Il n\u2019existe aucune autre solution ophtalmique de b\u00e9taxolol commercialis\u00e9e au Canada.\u00a0 Novartis a indiqu\u00e9 qu\u2019il s\u2019agit d\u2019une d\u00e9cision mondiale irr\u00e9versible. L\u2019arr\u00eat de commercialisation a d\u00e9j\u00e0 eu lieu dans […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cosprc.ca\/fr\/enonce-de-position-conjoint-sur-la-fin-a-la-commercialisation-du-betoptic-s\/\" \/>\n<meta property=\"og:site_name\" content=\"Practice Resource Centre\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-21T12:34:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-21T12:40:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cosprc.ca\/wp-content\/uploads\/2025\/05\/PRC-Joint-Statement-Banner-scaled.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1280\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Admin Assistant\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Admin Assistant\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/enonce-de-position-conjoint-sur-la-fin-a-la-commercialisation-du-betoptic-s\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/enonce-de-position-conjoint-sur-la-fin-a-la-commercialisation-du-betoptic-s\\\/\"},\"author\":{\"name\":\"Admin Assistant\",\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/#\\\/schema\\\/person\\\/9ab88c133cdbf69968d498a38588ee75\"},\"headline\":\"\u00c9nonc\u00e9 de position conjoint sur la fin \u00e0 la commercialisation du Betoptic S\",\"datePublished\":\"2025-05-21T12:34:40+00:00\",\"dateModified\":\"2025-05-21T12:40:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/enonce-de-position-conjoint-sur-la-fin-a-la-commercialisation-du-betoptic-s\\\/\"},\"wordCount\":551,\"image\":{\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/enonce-de-position-conjoint-sur-la-fin-a-la-commercialisation-du-betoptic-s\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cosprc.ca\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/PRC-Joint-Statement-Banner-1024x512.png\",\"articleSection\":[\"Pour les ophtalmologistes\",\"Pour les r\u00e9sidents et les boursiers\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/enonce-de-position-conjoint-sur-la-fin-a-la-commercialisation-du-betoptic-s\\\/\",\"url\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/enonce-de-position-conjoint-sur-la-fin-a-la-commercialisation-du-betoptic-s\\\/\",\"name\":\"\u00c9nonc\u00e9 de position conjoint sur la fin \u00e0 la commercialisation du Betoptic S - Practice Resource Centre\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/enonce-de-position-conjoint-sur-la-fin-a-la-commercialisation-du-betoptic-s\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/enonce-de-position-conjoint-sur-la-fin-a-la-commercialisation-du-betoptic-s\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cosprc.ca\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/PRC-Joint-Statement-Banner-1024x512.png\",\"datePublished\":\"2025-05-21T12:34:40+00:00\",\"dateModified\":\"2025-05-21T12:40:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/#\\\/schema\\\/person\\\/9ab88c133cdbf69968d498a38588ee75\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/enonce-de-position-conjoint-sur-la-fin-a-la-commercialisation-du-betoptic-s\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/enonce-de-position-conjoint-sur-la-fin-a-la-commercialisation-du-betoptic-s\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/enonce-de-position-conjoint-sur-la-fin-a-la-commercialisation-du-betoptic-s\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.cosprc.ca\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/PRC-Joint-Statement-Banner-1024x512.png\",\"contentUrl\":\"https:\\\/\\\/www.cosprc.ca\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/PRC-Joint-Statement-Banner-1024x512.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/enonce-de-position-conjoint-sur-la-fin-a-la-commercialisation-du-betoptic-s\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u00c9nonc\u00e9 de position conjoint sur la fin \u00e0 la commercialisation du Betoptic S\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/#website\",\"url\":\"https:\\\/\\\/www.cosprc.ca\\\/\",\"name\":\"Practice Resource Centre\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.cosprc.ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/#\\\/schema\\\/person\\\/9ab88c133cdbf69968d498a38588ee75\",\"name\":\"Admin Assistant\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1bb7ba3166135b524438491f96bc4d09514b58d4153f0c5fa19182fb727d6850?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1bb7ba3166135b524438491f96bc4d09514b58d4153f0c5fa19182fb727d6850?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1bb7ba3166135b524438491f96bc4d09514b58d4153f0c5fa19182fb727d6850?s=96&d=mm&r=g\",\"caption\":\"Admin Assistant\"},\"url\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/author\\\/h4gznwtqqyl8bwjg\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u00c9nonc\u00e9 de position conjoint sur la fin \u00e0 la commercialisation du Betoptic S - Practice Resource Centre","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cosprc.ca\/fr\/enonce-de-position-conjoint-sur-la-fin-a-la-commercialisation-du-betoptic-s\/","og_locale":"fr_FR","og_type":"article","og_title":"\u00c9nonc\u00e9 de position conjoint sur la fin \u00e0 la commercialisation du Betoptic S - Practice Resource Centre","og_description":"Novartis met fin \u00e0 la commercialisation du Betoptic S (b\u00e9taxolol 0,25\u00a0%) \u00e0 l\u2019\u00e9chelle mondiale. Les stocks existants au Canada devraient \u00eatre \u00e9puis\u00e9s d\u2019ici la fin de l\u2019ann\u00e9e. Il n\u2019existe aucune autre solution ophtalmique de b\u00e9taxolol commercialis\u00e9e au Canada.\u00a0 Novartis a indiqu\u00e9 qu\u2019il s\u2019agit d\u2019une d\u00e9cision mondiale irr\u00e9versible. L\u2019arr\u00eat de commercialisation a d\u00e9j\u00e0 eu lieu dans […]","og_url":"https:\/\/www.cosprc.ca\/fr\/enonce-de-position-conjoint-sur-la-fin-a-la-commercialisation-du-betoptic-s\/","og_site_name":"Practice Resource Centre","article_published_time":"2025-05-21T12:34:40+00:00","article_modified_time":"2025-05-21T12:40:04+00:00","og_image":[{"width":2560,"height":1280,"url":"https:\/\/www.cosprc.ca\/wp-content\/uploads\/2025\/05\/PRC-Joint-Statement-Banner-scaled.png","type":"image\/png"}],"author":"Admin Assistant","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Admin Assistant","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cosprc.ca\/fr\/enonce-de-position-conjoint-sur-la-fin-a-la-commercialisation-du-betoptic-s\/#article","isPartOf":{"@id":"https:\/\/www.cosprc.ca\/fr\/enonce-de-position-conjoint-sur-la-fin-a-la-commercialisation-du-betoptic-s\/"},"author":{"name":"Admin Assistant","@id":"https:\/\/www.cosprc.ca\/#\/schema\/person\/9ab88c133cdbf69968d498a38588ee75"},"headline":"\u00c9nonc\u00e9 de position conjoint sur la fin \u00e0 la commercialisation du Betoptic S","datePublished":"2025-05-21T12:34:40+00:00","dateModified":"2025-05-21T12:40:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cosprc.ca\/fr\/enonce-de-position-conjoint-sur-la-fin-a-la-commercialisation-du-betoptic-s\/"},"wordCount":551,"image":{"@id":"https:\/\/www.cosprc.ca\/fr\/enonce-de-position-conjoint-sur-la-fin-a-la-commercialisation-du-betoptic-s\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cosprc.ca\/wp-content\/uploads\/2025\/05\/PRC-Joint-Statement-Banner-1024x512.png","articleSection":["Pour les ophtalmologistes","Pour les r\u00e9sidents et les boursiers"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.cosprc.ca\/fr\/enonce-de-position-conjoint-sur-la-fin-a-la-commercialisation-du-betoptic-s\/","url":"https:\/\/www.cosprc.ca\/fr\/enonce-de-position-conjoint-sur-la-fin-a-la-commercialisation-du-betoptic-s\/","name":"\u00c9nonc\u00e9 de position conjoint sur la fin \u00e0 la commercialisation du Betoptic S - Practice Resource Centre","isPartOf":{"@id":"https:\/\/www.cosprc.ca\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cosprc.ca\/fr\/enonce-de-position-conjoint-sur-la-fin-a-la-commercialisation-du-betoptic-s\/#primaryimage"},"image":{"@id":"https:\/\/www.cosprc.ca\/fr\/enonce-de-position-conjoint-sur-la-fin-a-la-commercialisation-du-betoptic-s\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cosprc.ca\/wp-content\/uploads\/2025\/05\/PRC-Joint-Statement-Banner-1024x512.png","datePublished":"2025-05-21T12:34:40+00:00","dateModified":"2025-05-21T12:40:04+00:00","author":{"@id":"https:\/\/www.cosprc.ca\/#\/schema\/person\/9ab88c133cdbf69968d498a38588ee75"},"breadcrumb":{"@id":"https:\/\/www.cosprc.ca\/fr\/enonce-de-position-conjoint-sur-la-fin-a-la-commercialisation-du-betoptic-s\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cosprc.ca\/fr\/enonce-de-position-conjoint-sur-la-fin-a-la-commercialisation-du-betoptic-s\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.cosprc.ca\/fr\/enonce-de-position-conjoint-sur-la-fin-a-la-commercialisation-du-betoptic-s\/#primaryimage","url":"https:\/\/www.cosprc.ca\/wp-content\/uploads\/2025\/05\/PRC-Joint-Statement-Banner-1024x512.png","contentUrl":"https:\/\/www.cosprc.ca\/wp-content\/uploads\/2025\/05\/PRC-Joint-Statement-Banner-1024x512.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.cosprc.ca\/fr\/enonce-de-position-conjoint-sur-la-fin-a-la-commercialisation-du-betoptic-s\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cosprc.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"\u00c9nonc\u00e9 de position conjoint sur la fin \u00e0 la commercialisation du Betoptic S"}]},{"@type":"WebSite","@id":"https:\/\/www.cosprc.ca\/#website","url":"https:\/\/www.cosprc.ca\/","name":"Practice Resource Centre","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cosprc.ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.cosprc.ca\/#\/schema\/person\/9ab88c133cdbf69968d498a38588ee75","name":"Admin Assistant","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/1bb7ba3166135b524438491f96bc4d09514b58d4153f0c5fa19182fb727d6850?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/1bb7ba3166135b524438491f96bc4d09514b58d4153f0c5fa19182fb727d6850?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1bb7ba3166135b524438491f96bc4d09514b58d4153f0c5fa19182fb727d6850?s=96&d=mm&r=g","caption":"Admin Assistant"},"url":"https:\/\/www.cosprc.ca\/fr\/author\/h4gznwtqqyl8bwjg\/"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-26 18:22:06","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/posts\/31100","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/comments?post=31100"}],"version-history":[{"count":1,"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/posts\/31100\/revisions"}],"predecessor-version":[{"id":31101,"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/posts\/31100\/revisions\/31101"}],"wp:attachment":[{"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/media?parent=31100"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/categories?post=31100"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/post_tag?post=31100"},{"taxonomy":"content_type","embeddable":true,"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/content_type?post=31100"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}